Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oral-facial-digital syndrome 1 protein (OFD1) is a centrosomal and centriolar protein localized at the distal ends of centrioles and the basal body of primary cilia, as well as in the nucleus[1][3][5]. This protein is critical for regulating the length of centrioles, forming distal centriolar appendages, and recruiting intraflagellar transport proteins necessary for ciliogenesis[3]. OFD1 dysfunction results in defective primary cilia formation, abnormal signaling (including hedgehog and Wnt), and a spectrum of developmental disorders characterized by malformations of the face, oral cavity, digits, brain, and kidneys[2][4][5]. OFD1 mutations underlie the X-linked dominant developmental disorder known as oral-facial-digital syndrome type I, with broad phenotypic consequences and embryonic lethality in hemizygous males[4]. No small-molecule drugs or therapeutic agents are currently known to target OFD1 directly in clinical or research use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oral-facial-digital syndrome 1 protein (OFD1).